1. |
|
|
2. |
|
|
3. |
- Vesikari, Timo, et al.
(författare)
-
Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents.
- 2016
-
Ingår i: Journal of the Pediatric Infectious Diseases Society. - : Oxford University Press (OUP). - 2048-7207 .- 2048-7193.
-
Tidskriftsartikel (refereegranskat)abstract
- Neisseria meningitidis serogroup B (MnB) is a leading cause of invasive meningococcal disease in adolescents and young adults. A recombinant factor H binding protein (fHBP) vaccine (Trumenba(®); bivalent rLP2086) was recently approved in the United States in individuals aged 10-25 years. Immunogenicity and safety of 2- or 3-dose schedules of bivalent rLP2086 were assessed in adolescents.
|
|
4. |
|
|